Pharmacovigilance Case Intake ROI on Azure AI Foundry

Pharmacovigilance Case Intake ROI on Azure AI Foundry

1. Problem / Context

Pharmacovigilance (PV) teams in mid-market pharma and biotech face a stubborn operational equation: rising case volumes, expanding multilingual sources, and unrelenting EMA/FDA expectations for timeliness and traceability. Case intake is still labor-heavy—emails, call center transcripts, portal submissions, E2B files, and literature alerts arrive in varied formats and languages. Hours are spent normalizing data, translating narratives, and detecting duplicates across channels. During safety spikes, throughput becomes the bottleneck, and the only relief has been adding costly FTE capacity.

The business impact shows up directly in cost drivers: case intake and triage hours, translation spend, and duplicate case rework. At the same time, regulators expect full auditability and explainability across every decision. Mid-market firms—with lean teams and finite budgets—need a governed way to automate the routine while preserving inspection-grade controls. Azure AI Foundry provides the platform foundation, and a governed agentic approach—delivered with a partner like Kriv AI—turns it into real ROI.

2. Key Definitions & Concepts

• Pharmacovigilance case intake: The capture, normalization, and triage of Individual Case Safety Reports (ICSRs) from channels such as email, portals, E2B(R3) exchanges, call centers, and literature.
• Intake normalization: Extracting key entities (patient, reporter, suspect drug, event), mapping to controlled vocabularies (MedDRA, WHO Drug), and formatting to safety-database-ready structures.
• Deduplication: Identifying and resolving potential duplicates based on reporter, patient, event, product, and temporal proximity to avoid repeated effort and data quality issues.
• Agentic AI: A governed set of AI “agents” that coordinate tasks—ingest, extract, translate, dedupe, summarize, route—while enforcing human-in-the-loop review and maintaining full audit trails and lineage.
• Azure AI Foundry: Microsoft’s platform to build, evaluate, deploy, and govern AI systems using a catalog of models, prompt orchestration, evaluation frameworks, monitoring, and integration with Azure services (e.g., Document Intelligence, Translator, Search, and secure data services). It supports versioning, lineage, and policy controls that are critical for regulated operations.

3. Why This Matters for Mid-Market Regulated Firms

Mid-market PV groups carry the same compliance burden as Big Pharma but with far fewer people. The pressure comes from inspection readiness, rising literature obligations, multi-language intake, and unpredictable case surges. Cost and risk concentrate in a few places: time-to-triage, cases per FTE, translation cost per case, and error rate. Improving those metrics changes the unit economics of safety operations.

With governed agentic automation on Azure AI Foundry, firms can handle 30% more cases without adding headcount during safety spikes, shorten cycle times, and reduce duplicate rework—all while meeting EMA/FDA expectations for auditability and explainability. Kriv AI focuses on these mid-market realities, bringing governance, MLOps, and workflow orchestration so lean teams can scale safely and predictably.

4. Practical Implementation Steps / Roadmap

1) Connect intake sources

• Integrate email inboxes, portal uploads, call center transcripts, E2B(R3) gateways, and literature feeds.
• Use Azure Document Intelligence to parse PDFs and scanned attachments; leverage Azure AI Translator for narrative translation with source/target language detection.
• Normalize incoming payloads into a common schema suitable for your safety database (e.g., Argus, ArisGlobal) and internal review queues.

2) Extract and normalize key fields

• Use entity extraction to pull patient demographics, reporter details, suspect/concomitant products, events, dates, and seriousness criteria.
• Map events to MedDRA and products to WHO Drug using maintained dictionaries; enforce required-field checks.
• Generate a triage summary and a confidence score for auto-route vs. human review.

3) Deduplicate early and often

• Apply fuzzy matching and embeddings-based similarity on core identifiers (reporter, event terms, product, dates) to flag likely duplicates.
• Route duplicates to a dedicated human review step; auto-link related items when confidence is high to cut rework.

4) Automate literature scans

• Orchestrate weekly or daily searches across target journals/databases; summarize candidate articles and map them to existing cases or create new leads with clear provenance links.
• Maintain a watchlist for products/indications and set alert thresholds.

5) Governed agentic orchestration

• Build agentic workflows in Azure AI Foundry that sequence ingest → translate → extract → normalize → dedupe → summarize → route.
• Enforce human-in-the-loop for borderline cases; set thresholds that prevent over-automation.
• Track versions of prompts/models, datasets, and evaluation sets to sustain inspection-grade lineage.

6) Deploy, monitor, and iterate

• Start with a pilot queue (e.g., non-serious cases from two channels) and expand coverage in increments.
• Monitor throughput, exception rates, and reviewer overrides; continually refine thresholds and rules.
• Integrate with your CAPA/change-control process to keep validation current.

5. Governance, Compliance & Risk Controls Needed

• Audit trails and explainability: Log each agent action, model version, prompt, input, output, and reviewer decision; retain links to source artifacts for traceability during EMA/FDA inspections.
• Data protection and residency: Ensure PII handling with encryption at rest/in transit, access control (RBAC), and region-specific storage to meet GDPR and local requirements.
• Lineage and versioning: Maintain model/prompt/dataset lineage in Azure AI Foundry so every case decision is reproducible and attributable.
• Human oversight: Define thresholds for auto-approve, auto-flag, and mandatory human review. Document roles, SOPs, and escalation paths, including QPPV sign-off where required.
• Validation and change control: Treat models and workflows like validated systems—installation/operational/performance qualification (IQ/OQ/PQ), formal test evidence, and governed releases.
• Vendor lock-in mitigation: Favor standards (E2B(R3), MedDRA, WHO Drug), exportable lineage, and modular workflow components so you can swap models or services without rewriting the entire pipeline.

Kriv AI emphasizes governance-first delivery—tying every agentic step to lineage, approvals, and policies—so automation improves both efficiency and inspection readiness rather than trading one for the other.

6. ROI & Metrics

Focus measurement on operational levers that PV leaders control:

• Time-to-triage: Minutes from initial receipt to a triage decision.
• Cases per FTE: Throughput of reviewed cases per safety specialist.
• Translation cost per case: Spend on translating narratives and attachments.
• Error rate: Percentage of cases requiring correction or rework (including duplicates).

Concrete outcomes are achievable:

• Cutting average processing time per case from 90 minutes to 45 minutes by automating intake normalization and early deduplication.
• Lowering duplicate-related rework by 60% through systematic similarity checks and routing.
• Handling 30% more cases during spikes without adding headcount by freeing capacity via automation.

A sample mid-market scenario: At 12,000 cases/year and 90 minutes per case, you spend ~18,000 hours on intake. Reducing to 45 minutes saves ~9,000 hours. At a blended cost of $70/hour, that’s ~$630,000 annual labor savings. If translation currently averages $18/case and automation eliminates 40% of that (via selective, high-confidence translation and reuse), that’s another ~$86,000 saved. Combined with reduced error-driven rework, a 6–12 month payback is realistic for a staged rollout that starts with two or three channels and scales.

Kriv AI helps leadership stand up an ROI dashboard that blends cycle-time, queue depth, reviewer overrides, translation spend, and duplicate rates—so value is visible week by week, not just at quarter close.

7. Common Pitfalls & How to Avoid Them

• Over-automation without thresholds: Always keep human-in-the-loop gates where confidence is low; tune thresholds using historical “golden” cases.
• Weak dedup logic: Combine rules, fuzzy matching, and embeddings; review and label borderline pairs to improve over time.
• Ungoverned translation: Maintain source-target language logs and store original texts alongside translations for auditability.
• Skipping validation: Treat workflow changes as controlled releases with test evidence; involve QA/RA and QPPV early.
• Poor dictionary hygiene: Keep MedDRA/WHO Drug dictionaries synchronized; schedule reconciliation tasks.
• Not integrating the safety database: Integrate bi-directionally so case state changes flow back to the intake system.
• Ignoring literature provenance: Store citations, abstracts, and retrieval metadata for inspection-ready traceability.

30/60/90-Day Start Plan

First 30 Days

• Discovery: Map all intake channels, case volumes, languages, and seasonality. Inventory existing SOPs and validation artifacts.
• Data checks: Assess document formats, OCR quality, and dictionary versions; identify PII handling requirements and regional data residency constraints.
• Governance boundaries: Define human review thresholds, approval roles, and audit log requirements; align with QA/RA and the QPPV.
• Technical blueprint: Outline Azure AI Foundry components, safety database interfaces, and monitoring needs.

Days 31–60

• Pilot build: Implement a narrow-scope workflow (e.g., email + portal, non-serious cases). Include translation, extraction, and dedup.
• Agentic orchestration: Configure stepwise agents and review queues; enable prompt/model versioning with lineage.
• Security controls: Enforce RBAC, encryption, and environment separation (dev/test/prod). Capture audit trails end to end.
• Evaluation: Run against a labeled historical set; calibrate thresholds to minimize false negatives on serious cases.

Days 61–90

• Scale coverage: Add call center transcripts, E2B gateway, and literature scanning. Expand to additional products/regions.
• Monitoring and metrics: Stand up operational dashboards for cycle time, duplicate rate, reviewer overrides, and translation spend.
• Stakeholder alignment: Formalize SOP updates, training, and change control. Define ongoing maintenance of dictionaries and models.
• Business case update: Recalculate savings with real data; plan next-phase automation (e.g., auto-draft of E2B fields for review).

9. Industry-Specific Considerations

• Standards: Ensure conformance with ICH E2B(R3) for ICSR structure and use current MedDRA and WHO Drug dictionaries.
• Roles: Align with QPPV responsibilities and ensure timely reporting to EudraVigilance/FAERS.
• Privacy: Manage GDPR-compliant handling of personal data in narratives and attachments; apply minimization and secure storage.
• Validation: Maintain IQ/OQ/PQ documentation and test evidence for each workflow change; link to CAPA where relevant.

10. Conclusion / Next Steps

Automating PV case intake on Azure AI Foundry is a practical, governed path to better throughput, lower cost, and stronger inspection readiness. By targeting concrete levers—time-to-triage, cases per FTE, translation cost per case, and duplicate rework—mid-market teams can see payback in 6–12 months while improving quality and consistency.

As a governed AI and agentic automation partner, Kriv AI helps regulated mid-market companies turn Azure AI Foundry into production-grade PV workflows—linking data readiness, MLOps, and governance so automation scales without compromising compliance. If you’re exploring governed Agentic AI for your mid-market organization, Kriv AI can serve as your operational and governance backbone.